Overview of the clinical relevance of autologous bone marrow transplantation.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004341:Drug Evaluation; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D006801:Humans; D007938:Leukemia / Q000628:therapy; D007945:Leukemia, Lymphoid / Q000628:therapy; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013866:Thioguanine / Q000627:therapeutic use; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D003561:Cytarabine; D005047:Etoposide; D003520:Cyclophosphamide; D013866:Thioguanine; D008558:Melphalan; D002330:Carmustine